| Literature DB >> 35146378 |
Joshua M Landman1,2, Karen Steger-May3, Karen E Joynt Maddox4, Gmerice Hammond4, Aditi Gupta1,3, Adriana M Rauseo5, Min Zhao1, Randi E Foraker1,6.
Abstract
OBJECTIVE: To estimate the risk of hospital admission and mortality from COVID-19 to patients and measure the association of race and area-level social vulnerability with those outcomes.Entities:
Keywords: COVID-19; hospital admission; mortality; social determinants of health; social vulnerability
Year: 2021 PMID: 35146378 PMCID: PMC8822405 DOI: 10.1093/jamiaopen/ooab111
Source DB: PubMed Journal: JAMIA Open ISSN: 2574-2531
Patient characteristics at first COVID-19 positive test overall and by race for 8041 patients who first tested positive between 7 April 2020 and 31 October 2020
| Characteristic | Overall (No. = 8041) | By race | |||||
|---|---|---|---|---|---|---|---|
| White (No. = 4494) | Black (No. = 3547) | ||||||
| No. | Summary statistic | No. | Summary statistic | No. | Summary statistic | ||
| Demographics | |||||||
| SVI percentile, median (IQR), range | 8041 | 45.1 (54.9), 0.1 to 99.7 | 4494 | 28.6 (40.9), 0.1 to 99.7 | 3547 | 68.4 (36.9), 0.1 to 99.7 | <.0001 |
| SVI category, no. (%) | 8041 | 4494 | 3547 | <.0001 | |||
| Most socially advantaged | 2657 (33.0%) | 2133 (47.5%) | 524 (14.8%) | ||||
| Middle | 2666 (33.2%) | 1590 (35.4%) | 1076 (30.3%) | ||||
| Most socially disadvantaged | 2718 (33.8%) | 771 (17.2%) | 1947 (54.9%) | ||||
| Pandemic time course category, no. (%) | 8041 | 4494 | 3547 | <.0001 | |||
| Early | 2322 (28.9%) | 929 (20.7%) | 1393 (39.3%) | ||||
| Middle | 3113 (38.7%) | 1679 (37.4%) | 1434 (40.4%) | ||||
| Late | 2606 (32.4%) | 1886 (42.0%) | 720 (20.3%) | ||||
| Age (y), mean (SD), range | 8041 | 48.2 (21.3), 0 to 103 | 4494 | 50.0 (22.1), 0 to 102 | 3547 | 46.0 (20.2), 0 to 103 | <.0001 |
| Age category (y), no. (%) | 8041 | 4494 | 3547 | <.0001 | |||
| 0–19 | 675 (8.4%) | 410 (9.1%) | 265 (7.5%) | ||||
| 20–49 | 3430 (42.7%) | 1701 (37.8%) | 1729 (48.8%) | ||||
| 50–64 | 1931 (24.0%) | 1077 (24.0%) | 854 (24.1%) | ||||
| 65–74 | 1057 (13.2%) | 676 (15.0%) | 381 (10.7%) | ||||
| ≥75 | 948 (11.8%) | 630 (14.0%) | 318 (9.0%) | ||||
| Gender, no. (%) | 8041 | 4494 | 3547 | .019 | |||
| Female | 4810 (59.8%) | 2637 (58.7%) | 2173 (61.3%) | ||||
| Male | 3231 (40.2%) | 1857 (41.3%) | 1374 (38.7%) | ||||
| Elixhauser comorbidities | |||||||
| AHRQ Elixhauser Mortality Index, median (IQR), range | 6823 | 0 (2), -22 to +51 | 3889 | 0 (0), -22 to +45 | 2934 | 0 (3), -14 to +51 | .001 |
| AHRQ Elixhauser Mortality Index category, no. (%) | 6823 | 3889 | 2934 | <.0001 | |||
| Least disease burden | 4979 (73.0%) | 3001 (77.2%) | 1978 (67.4%) | ||||
| Middle | 720 (10.6%) | 319 (8.2%) | 401 (13.7%) | ||||
| Most disease burden | 1124 (16.5%) | 569 (14.6%) | 555 (18.9%) | ||||
| Presence of the 5 most prevalent AHRQ comorbidities | |||||||
| Hypertension, uncomplicated or complicated, no. (%) | 6823 | 1867 (27.4%) | 3889 | 866 (22.3%) | 2934 | 1001 (34.1%) | <.0001 |
| Diabetes, uncomplicated, no. (%) | 6823 | 908 (13.3%) | 3889 | 370 (9.5%) | 2934 | 538 (18.3%) | <.0001 |
| Chronic pulmonary disease, no. (%) | 6823 | 874 (12.8%) | 3889 | 393 (10.1%) | 2934 | 481 (16.4%) | <.0001 |
| Depression, no. (%) | 6823 | 474 (6.9%) | 3889 | 291 (7.5%) | 2934 | 183 (6.2%) | .045 |
| Fluid and electrolyte disorders, no. (%) | 6823 | 418 (6.1%) | 3889 | 192 (4.9%) | 2934 | 226 (7.7%) | <.0001 |
Abbreviations: AHRQ: Agency for Healthcare Research and Quality; IQR: interquartile range defined as the 75th minus the 25th percentile; No./no.: number of patients; SD: standard deviation; SVI: Social Vulnerability Index; y: year; %: percent of the sample represented by the column.
a P-value compares characteristics for White versus Black patients by Wilcoxon’s test.
b P-value compares characteristics for White versus Black patients by chi-square test.
c P-value compares characteristics for White versus Black patients by unpaired t-test.
d Comorbidities reflect data that are available within ±2 days of the first positive COVID-19 test.
Association of patient characteristics at first COVID-19 positive test with the likelihood of COVID-related hospital admission
| Population | Characteristic | No. (% of category admitted) | Univariable model | Multivariable model | ||
|---|---|---|---|---|---|---|
| OR (95% CI) | aOR (95% CI) | |||||
| COVID-19 positive | Race | |||||
| (No. = 8041) | White | 1244 (27.7%) | referent | referent | ||
| Black | 2048 (57.7%) | 3.57 (3.18–4.00) | <.0001 | 3.92 (3.43–4.49) | <.0001 | |
| SVI category | ||||||
| Most socially advantaged | 808 (30.4%) | referent | referent | |||
| Middle | 1036 (38.9%) | 1.45 (1.23–1.72) | <.0001 | 1.13 (0.97–1.32) | .10 | |
| Most socially disadvantaged | 1448 (53.3%) | 2.61 (2.26–3.02) | <.0001 | 1.49 (1.28–1.73) | <.0001 | |
| Pandemic time course category | ||||||
| Early | 1128 (48.6%) | 1.68 (1.47–1.92) | <.0001 | 0.99 (0.86–1.14) | .89 | |
| Middle | 1227 (39.4%) | 1.16 (1.04–1.30) | .010 | 0.96 (0.85–1.09) | .54 | |
| Late | 937 (36.0%) | referent | referent | |||
| Age category (y) | ||||||
| 0–19 | 197 (29.2%) | referent | referent | |||
| 20–49 | 1213 (35.4%) | 1.33 (1.11–1.58) | .002 | 1.21 (1.00–1.45) | .049 | |
| 50–64 | 746 (38.6%) | 1.53 (1.26–1.85) | <.0001 | 1.52 (1.25–1.84) | <.0001 | |
| 65–74 | 519 (49.1%) | 2.34 (1.90–2.89) | <.0001 | 2.79 (2.23–3.48) | <.0001 | |
| ≥75 | 617 (65.1%) | 4.52 (3.59–5.69) | <.0001 | 6.01 (4.72–7.65) | <.0001 | |
| Gender | ||||||
| Female | 1812 (37.7%) | referent | referent | |||
| Male | 1480 (45.8%) | 1.40 (1.27–1.54) | <.0001 | 1.42 (1.28–1.57) | <.0001 | |
| COVID-19 positive, | Race | |||||
| subgroup with nonmissing | White | 1085 (27.9%) | referent | referent | ||
| comorbidity data | Black | 1878 (64.0%) | 4.60 (4.11–5.14) | <.0001 | 4.55 (3.95–5.24) | <.0001 |
| (No. = 6823) | ||||||
| SVI category | ||||||
| Most socially advantaged | 742 (31.7%) | referent | referent | |||
| Middle | 906 (41.1%) | 1.50 (1.24–1.81) | <.0001 | 1.13 (0.96–1.33) | .13 | |
| Most socially disadvantaged | 1315 (57.7%) | 2.94 (2.52–3.44) | <.0001 | 1.47 (1.25–1.73) | <.0001 | |
| Pandemic time course category | ||||||
| Early | 970 (54.4%) | 2.09 (1.81–2.42) | <.0001 | 1.13 (0.96–1.33) | .13 | |
| Middle | 1145 (42.3%) | 1.29 (1.14–1.45) | <.0001 | 1.01 (0.88–1.16) | .88 | |
| Late | 848 (36.3%) | referent | referent | |||
| Age category (y) | ||||||
| 0–19 | 197 (32.4%) | referent | referent | |||
| 20–49 | 1156 (39.4%) | 1.36 (1.13–1.63) | .001 | 1.23 (1.01–1.50) | .038 | |
| 50–64 | 667 (40.3%) | 1.40 (1.15–1.72) | .001 | 1.26 (1.02–1.56) | .031 | |
| 65–74 | 445 (48.4%) | 1.95 (1.56–2.44) | <.0001 | 1.79 (1.40–2.28) | <.0001 | |
| ≥75 | 498 (70.1%) | 4.89 (3.84–6.23) | <.0001 | 4.66 (3.57–6.09) | <.0001 | |
| Gender | ||||||
| Female | 1641 (39.8%) | referent | referent | |||
| Male | 1322 (48.9%) | 1.44 (1.31–1.60) | <.0001 | 1.46 (1.31–1.63) | <.0001 | |
| AHRQ Elixhauser Mortality Index category | ||||||
| Least disease burden | 1769 (35.5%) | referent | referent | |||
| Middle | 444 (61.7%) | 2.92 (2.47–3.45) | <.0001 | 2.26 (1.88–2.73) | <.0001 | |
| Most disease burden | 750 (66.7%) | 3.64 (3.19–4.15) | <.0001 | 2.39 (2.03–2.81) | <.0001 | |
Abbreviations: AHRQ: Agency for Healthcare Research and Quality; aOR: adjusted odds ratio; CI: confidence interval for the OR; No./no.: number of patients; OR: unadjusted odds ratio; SVI: Social Vulnerability Index; y: year; %: percent of the row category that were admitted.
a For COVID-positive patients, unadjusted odds ratio and P-value are calculated from univariable generalized estimating equations modeling the probability of COVID-related hospital admission for each category as compared to the referent.
b For COVID-positive patients, adjusted odds ratio and P-value are calculated from multivariable generalized estimating equations model of characteristics associated with the probability of COVID-related hospital admission, after adjusting for all other characteristics in the model.
c Comorbidities reflect data that are available within ±2 days of the first positive COVID-19 test.
Association of patient characteristics with the likelihood of in-hospital mortality among patients with a positive COVID-19 test result and a COVID-related hospital admission
| Population | Characteristic | No. (% of category that died) | Univariable model | Multivariable model | |||
|---|---|---|---|---|---|---|---|
| OR (95% CI) | aOR (95% CI) | ||||||
| COVID-related hospital admission | Race | ||||||
| (No. = 3292) | White | 108 (8.7%) | referent | referent | |||
| Black | 115 (5.6%) | 0.63 (0.47, 0.84) | .002 | 0.96 (0.68, 1.34) | .80 | ||
| SVI category | |||||||
| Most socially advantaged | 66 (8.2%) | referent | referent | ||||
| Middle | 67 (6.5%) | 0.78 (0.54, 1.13) | .19 | 0.82 (0.54, 1.24) | .34 | ||
| Most socially disadvantaged | 90 (6.2%) | 0.75 (0.52, 1.07) | .11 | 0.99 (0.67, 1.45) | .95 | ||
| Pandemic time course category | |||||||
| Early | 133 (11.8%) | 2.92 (2.02, 4.22) | <.0001 | 2.95 (2.02, 4.33) | <.0001 | ||
| Middle | 49 (4.0%) | 0.91 (0.61, 1.35) | .63 | 1.40 (0.94, 2.09) | .10 | ||
| Late | 41 (4.4%) | referent | referent | ||||
| Age category (y) | |||||||
| 0–49 | 7 (0.5%) | referent | referent | ||||
| 50–64 | 39 (5.2%) | 11.06 (4.98, 24.52) | <.0001 | 9.85 (4.40, 22.04) | <.0001 | ||
| 65–74 | 54 (10.4%) | 23.28 (10.54, 51.41) | <.0001 | 21.14 (9.49, 47.12) | <.0001 | ||
| ≥75 | 123 (19.9%) | 49.90 (23.41, 106.4) | <.0001 | 43.93 (20.18, 95.60) | <.0001 | ||
| Gender | |||||||
| Female | 98 (5.4%) | referent | referent | ||||
| Male | 125 (8.4%) | 1.61 (1.26, 2.07) | .0002 | 1.49 (1.15, 1.93) | .003 | ||
| COVID-related hospital admission, | Race | ||||||
| subgroup with nonmissing | White | 107 (9.8%) | referent | referent | |||
| comorbidity data | Black | 114 (6.0%) | 0.59 (0.44, 0.79) | .0004 | 0.82 (0.57, 1.17) | .27 | |
| SVI category | |||||||
| Most socially advantaged | 66 (8.8%) | referent | referent | ||||
| Middle | 67 (7.3%) | 0.82 (0.57, 1.17) | .27 | 0.92 (0.62, 1.37) | .70 | ||
| Most socially disadvantaged | 88 (6.6%) | 0.73 (0.51, 1.05) | .09 | 1.06 (0.72, 1.56) | .76 | ||
| Pandemic time course category: | |||||||
| Early | 132 (13.4%) | 3.06 (2.12, 4.41) | <.0001 | 3.20 (2.15, 4.77) | <.0001 | ||
| Middle | 48 (4.2%) | 0.87 (0.59, 1.28) | .48 | 1.39 (0.92, 2.09) | .11 | ||
| Late | 41 (4.8%) | referent | referent | ||||
| Age category (y) | |||||||
| 0–49 | 7 (0.5%) | referent | referent | ||||
| 50–64 | 39 (5.8%) | 11.78 (5.31, 26.15) | <.0001 | 8.71 (3.83, 19.81) | <.0001 | ||
| 65–74 | 52 (11.5%) | 25.08 (11.33, 55.53) | <.0001 | 15.61 (6.75, 36.10) | <0.0001 | ||
| ≥75 | 123 (24.6%) | 62.62 (29.36, 133.5) | <.0001 | 37.22 (16.44, 84.24) | <.0001 | ||
| Gender | |||||||
| Female | 98 (5.9%) | referent | referent | ||||
| Male | 123 (9.2%) | 1.61 (1.26, 2.07) | .0002 | 1.52 (1.16, 2.01) | .003 | ||
| AHRQ Elixhauser Mortality Index category | |||||||
| Least disease burden | 58 (3.3%) | referent | .024 | referent | .17 | ||
| Middle | 27 (5.8%) | 1.77 (1.08, 2.89) | <.0001 | 1.42 (0.86, 2.34) | <.0001 | ||
| Most disease burden | 136 (17.5%) | 6.11 (4.34, 8.60) | 2.30 (1.58, 3.36) | ||||
Abbreviations: AHRQ: Agency for Healthcare Research and Quality; aOR: adjusted odds ratio; CI: confidence interval for the OR; No./no.: number of patients; OR: unadjusted odds ratio; SVI: Social Vulnerability Index; y: year; %: percent of the row category that died.
a For COVID-positive patients who underwent a COVID-related hospitalization, unadjusted odds ratio and P-value are calculated from univariable generalized estimating equations modeling the probability of in-hospital mortality for each category as compared to the referent.
b For COVID-positive patients who underwent a COVID-related hospitalization, adjusted odds ratio and P-value are calculated from multivariable generalized estimating equations model of characteristics associated with the probability of in-hospital mortality, after adjusting for all other characteristics in the model.
c Due to zero deaths in patients less than 20 years old, the 0–19 and 20–49 category were combined for analyses.
d Comorbidities reflect data that are available within ±2 days of the COVID-related admission.